{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T06:54:31Z","timestamp":1792652071616,"version":"4.5.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,7,26]],"date-time":"2019-07-26T00:00:00Z","timestamp":1564099200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,7,26]],"date-time":"2019-07-26T00:00:00Z","timestamp":1564099200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012895","name":"Zoetis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012895","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Parasites Vectors"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13071-019-3632-3","type":"journal-article","created":{"date-parts":[[2019,7,26]],"date-time":"2019-07-26T13:02:27Z","timestamp":1564146147000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["ProHeart\u00ae 12, a moxidectin extended-release injectable formulation for prevention of heartworm (Dirofilaria immitis) disease in dogs in the USA for 12\u00a0months"],"prefix":"10.1186","volume":"12","author":[{"given":"Tom L.","family":"McTier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Kryda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Wachowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Mahabir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Ramsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doug","family":"Rugg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Mazaleski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Therrien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Wolff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dwight D.","family":"Bowman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,26]]},"reference":[{"key":"3632_CR1","doi-asserted-by":"publisher","first-page":"196","DOI":"10.3389\/fphys.2012.00196","volume":"3","author":"R Morchon","year":"2012","unstructured":"Morchon R, Carreton E, Gonzalez-Miguel J, Mellado-Hernandez I. Heartworm disease (Dirofilaria immitis) and their vectors in Europe\u2014new distribution trends. Front Physiol. 2012;3:196.","journal-title":"Front Physiol."},{"key":"3632_CR2","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/1756-3305-7-206","volume":"7","author":"C Genchi","year":"2014","unstructured":"Genchi C, Bowman D, Drake J. Canine HW disease (Dirofilaria immitis) in western Europe: survey of veterinary awareness and perceptions. Parasit Vectors. 2014;7:206.","journal-title":"Parasit Vectors."},{"key":"3632_CR3","unstructured":"Rehm J. AHS survey finds increase in HW Cases from 2013\u20132016. American Heartworm Society Quarterly Update; 2017. \n                              https:\/\/www.heartwormsociety.org\/veterinary-resources\/veterinary-education\/ahs-board-speaks-out\/368-ahs-survey-finds-increase-in-heartworm-cases\n                              \n                           . Accessed 19 Oct 2018."},{"key":"3632_CR4","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13071-018-2631-0","volume":"11","author":"J Drake","year":"2018","unstructured":"Drake J, Wiseman S. Increasing incidence of Dirofilaria immitis in dogs in USA with focus on the southeast region 2013\u20132016. Parasit Vectors. 2018;11:39.","journal-title":"Parasit Vectors."},{"key":"3632_CR5","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1186\/s13071-018-2845-1","volume":"11","author":"V \u010cabanov\u00e1","year":"2018","unstructured":"\u010cabanov\u00e1 V, Miterp\u00e1kov\u00e1 M, Valentov\u00e1 D, Bla\u017eejov\u00e1 H, Rudolf I, Stloukal E, et al. Urbanization impact on mosquito community and the transmission potential of filarial infection in central Europe. Parasit Vectors. 2018;11:261.","journal-title":"Parasit Vectors."},{"key":"3632_CR6","unstructured":"Heartgard-30\u00ae Freedom of Information Summary. 1987. \n                              https:\/\/animaldrugsatfda.fda.gov\/adafda\/app\/search\/public\/document\/downloadFoi\/420\n                              \n                           . Accessed 22 Apr 2019."},{"key":"3632_CR7","unstructured":"Grieve RB, Frank GR, Stewart VA, Parsons JC, Abraham D, MacWilliams PS, et al. Effect of dosage and dose timing on heartworm (Dirofilaria immitis) chemoprophylaxis with milbemycin. In: Otto GF, editor. Proceedings of the Heartworm Symposium \u02bc89. Washington DC: American Heartworm Society; 1989. p. 121\u20134."},{"key":"3632_CR8","unstructured":"McTier, TL, McCall JW, Dzimianski MT, Aguilar R, Wood I. Prevention of experimental heartworm infection in dogs with single oral doses of moxidectin. In: Soll MD, editor. Proceedings of the Heartworm Symposium \u02bc92. Batavia, IL: American Heartworm Society; 1992. p. 165\u20138."},{"key":"3632_CR9","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/S0304-4017(00)00297-1","volume":"91","author":"TL McTier","year":"2000","unstructured":"McTier TL, Shanks DJ, Watson P, McCall JW, Genchi C, Six RH, et al. Prevention of experimentally induced heartworm Dirofilaria immitis infections in dogs and cats with a single topical application of selamectin. Vet Parasitol. 2000;91:259\u201368.","journal-title":"Vet Parasitol."},{"key":"3632_CR10","first-page":"149","volume-title":"Recent Advances in Heartworm Disease\u2014Symposium \u201901","author":"JB Lok","year":"2001","unstructured":"Lok JB, Knight DH, McCall JW, Dzimianski MT, Cleale RM, Wang GT, et al. Six-month prophylactic efficacy of an injectable, sustained-release formulation of moxidectin against Dirofilaria immitis infection: a two-center study. In: Seward HL, editor. Recent Advances in Heartworm Disease\u2014Symposium \u201901. Batavia: American Heartworm Society; 2001. p. 149\u201357."},{"key":"3632_CR11","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.2460\/ajvr.2001.62.1721","volume":"62","author":"JB Lok","year":"2001","unstructured":"Lok JB, Knight DH, Wang GT, Doscher ME, Nolan TJ, Hendrick MJ, et al. Activity of an injectable, sustained-release formulation of moxidectin administered prophylactically to mixed-breed dogs to prevent infection with Dirofilaria immitis. Am J Vet Res. 2001;62:1721\u20136.","journal-title":"Am J Vet Res."},{"issue":"97","key":"3632_CR12","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1007\/s00436-005-1448-x","volume":"2005","author":"RG Arther","year":"2005","unstructured":"Arther RG, Bowman DD, Slone RL, Travis LE. Imidacloprid plus moxidectin topical solution for the prevention of HW disease (Dirofilaria immitis) in dogs. Parasitol Res. 2005;2005(97):76\u201380.","journal-title":"Parasitol Res."},{"key":"3632_CR13","unstructured":"American Heartworm Society. Resistance Statement. 2014. \n                              https:\/\/www.heartwormsociety.org\/images\/pdf\/Resistance_statement_FINAL.pdf\n                              \n                           . Accessed 23 Oct 2018."},{"key":"3632_CR14","unstructured":"American Heartworm Society. Current canine guidelines for the prevention, diagnosis, and management of heartworm (Dirofilaria immitis) infection in dogs. 2018. \n                              https:\/\/www.heartwormsociety.org\/images\/pdf\/2018-AHS-Canine-Guidelines.pdf\n                              \n                           . Accessed 23 Oct 2018."},{"key":"3632_CR15","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.vetpar.2014.08.013","volume":"206","author":"CE Atkins","year":"2014","unstructured":"Atkins CE, Murray MJ, Olavessen LJ, Burton KW, Marshall JW, Brooks CC. Heartworm \u2018lack of effectiveness\u2019 claims in the Mississippi delta: computerized analysis of owner compliance, 2004\u20132011. Vet Parasitol. 2014;206:106\u201313.","journal-title":"Vet Parasitol."},{"key":"3632_CR16","unstructured":"American Heartworm Society. Survey of U.S. veterinarians uncovers per-practice increase in heartworm-positive cases. 2017. \n                              https:\/\/heartwormsociety.org\/newsroom\/in-the-news\/347-ahs-announces-findings-of-new-heartworm-incidence-survey\n                              \n                           . Accessed 17 Sep 2018."},{"key":"3632_CR17","unstructured":"Companion Animal Parasite Council (CAPC). CAPC Guidelines: Heartworm. 2016. \n                              https:\/\/capcvet.org\/guidelines\/heartworm\/\n                              \n                           . Accessed 14 Jul 2019."},{"key":"3632_CR18","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1186\/s13071-014-0494-6","volume":"7","author":"CN Pulaski","year":"2014","unstructured":"Pulaski CN, Malone JB, Bourguinat C, Prichard R, Geary T, Ward DR, et al. Establishment of macrocyclic lactone resistant Dirofilaria immitis isolates in experimentally infected laboratory dogs. Parasit Vectors. 2014;7:494.","journal-title":"Parasit Vectors."},{"key":"3632_CR19","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.vetpar.2015.04.002","volume":"210","author":"C Bourguinat","year":"2015","unstructured":"Bourguinat C, Lee A, Lizunda R, Blagburn B, Liotta J, Kraus M, et al. Macrocyclic lactone resistance in Dirofilaria immitis: failure of heartworm preventives and investigation of genetic markers for resistance. Vet Parasitol. 2015;210:167\u201378.","journal-title":"Vet Parasitol."},{"issue":"Suppl. 2","key":"3632_CR20","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1186\/s13071-017-2436-6","volume":"10","author":"MJ Maclean","year":"2017","unstructured":"Maclean MJ, Savadelis MD, Coates R, Dzimianski M, Jones C, Benbow C, et al. Do the effects of macrocyclic lactones on microfilarial motility in vitro reflect the resistance status of Dirofilaria immitis isolates? Parasit Vectors. 2017;10(Suppl. 2):480.","journal-title":"Parasit Vectors."},{"key":"3632_CR21","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s13071-016-1476-7","volume":"9","author":"BL Blagburn","year":"2016","unstructured":"Blagburn BL, Arther RG, Dillon AR, Butler JM, Bowles JV, von Simpson C, Zolynas R. Efficacy of four commercially available heartworm preventive products against the JYD-34 laboratory strain of Dirofilaria immitis. Parasit Vectors. 2016;9:191.","journal-title":"Parasit Vectors."},{"issue":"Suppl. 2","key":"3632_CR22","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1186\/s13071-017-2429-5","volume":"10","author":"TL McTier","year":"2017","unstructured":"McTier TL, Six RH, Pullins A, Chapin S, McCall JW, Rugg D, et al. Efficacy of oral moxidectin against susceptible and resistant isolates of Dirofilaria immitis in dogs. Parasit Vectors. 2017;10(Suppl. 2):482.","journal-title":"Parasit Vectors."},{"key":"3632_CR23","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.ijpddr.2018.06.006","volume":"8","author":"C Ballesteros","year":"2018","unstructured":"Ballesteros C, Pulaski CN, Bourguinat C, Keller K, Prichard RK, Geary TG. Clinical validation of molecular markers of macrocyclic lactone resistance in Dirofilaria immitis. Int J Parasitol Drugs Drug Resist. 2018;8:596\u2013606.","journal-title":"Int J Parasitol Drugs Drug Resist."},{"key":"3632_CR24","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.2460\/ajvr.2004.65.1596","volume":"65","author":"M Holm-Martin","year":"2004","unstructured":"Holm-Martin M, Atwell R. Evaluation of a single injection of a sustained-release formulation of moxidectin for prevention of experimental HW infection after 12\u00a0months in dogs. Am J Vet Res. 2004;65:1596\u20139.","journal-title":"Am J Vet Res."},{"key":"3632_CR25","unstructured":"Center for Veterinary Medicine. Effectiveness of anthelmintics: general recommendations. VICH GL7 Technical Report, October 2001. Rockville, MD: CVM; 2001."},{"key":"3632_CR26","unstructured":"Center for Veterinary Medicine. Effectiveness of anthelmintics: specific recommendations for canine. VICH GL19 Technical Report, June 2002. Rockville, MD: CVM; 2002."},{"key":"3632_CR27","unstructured":"McCall JW, Lindemann BA, Porter CA. Prophylactic activity of avermectins against experimentally induced Dirofilaria immitis infections in dogs. In: Otto GF, editor. Proceedings of the Heartworm Symposium \u201980. Edwardsville, KS: Veterinary Medicine Publishing Co; 1980. p. 126\u201330."},{"key":"3632_CR28","first-page":"1341","volume":"47","author":"RA Holmes","year":"1986","unstructured":"Holmes RA, McCall JW, Prasse KW. Thiacetarsamide in dogs with Dirofilaria immitis: influence of decreased liver function on drug efficacy. Am J Vet Res. 1986;47:1341.","journal-title":"Am J Vet Res."},{"key":"3632_CR29","doi-asserted-by":"crossref","unstructured":"Krautmann MJ, Ervin, T, Mahabir S, Fielder A, Collard W, Wolthius TL, et al. Safety of an extended-release injectable moxidectin suspension formulation (ProHeart 12) in dogs. Parasit Vectors. 2019 (In Press).","DOI":"10.1186\/s13071-019-3690-6"},{"key":"3632_CR30","unstructured":"McCall JW, McTier TL, Holmes RA, Greene T, Strickland J, Aguilar R. Prevention of naturally acquired HW infection in HW-naive beagles by oral administration of moxidectin at an interval of either one or two months. In: Soll, MD, editor. Proceedings of the HW Symposium \u02bc92. Batavia, IL: American Heartworm Society; 1992. p. 169\u201377."},{"key":"3632_CR31","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13071-016-1293-z","volume":"9","author":"DD Bowman","year":"2016","unstructured":"Bowman DD, Grazette AR, Basel C, Wang Y, Hostetler JA. Protection of dogs against canine heartworm infection 28 days after four monthly treatments with Advantage Multi\u00ae for dogs. Parasit Vectors. 2016;9:12.","journal-title":"Parasit Vectors."},{"issue":"Suppl. 2","key":"3632_CR32","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1186\/s13071-017-2432-x","volume":"10","author":"DD Bowman","year":"2017","unstructured":"Bowman DD, Ohmes CM, Hostetler JA, Keil DJ, Settje TL, Charles SD. Efficacy of 10% imidacloprid + 2.5% moxidectin topical solution (Advantage Multi\u00ae for Dogs) for the prevention of HW disease and infection all month long. Parasit Vectors. 2017;10(Suppl. 2):478.","journal-title":"Parasit Vectors"},{"issue":"Suppl. 2","key":"3632_CR33","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1186\/s13071-017-2431-y","volume":"10","author":"DD Bowman","year":"2017","unstructured":"Bowman DD, McTier TL, Adams EL, Mahabir SP, Login JA, Bidgood T, Woods DJ. Evaluation of the efficacy of ProHeart\u00ae 6 (moxidectin) against a resistant isolate of Dirofilaria immitis (JYD-34) in dogs. Parasit Vectors. 2017;10(Suppl. 2):502.","journal-title":"Parasit Vectors."},{"key":"3632_CR34","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1002\/bdd.572","volume":"28","author":"SI Al-Azzam","year":"2007","unstructured":"Al-Azzam SI, Fleckenstein L, Cheng KJ, Dzimanski MT, McCall JW. Comparison of the pharmacokinetics of moxidectin and ivermectin after oral administration to beagle dogs. Biopharm Drug Dispos. 2007;28:431.","journal-title":"Biopharm Drug Dispos."},{"key":"3632_CR35","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.ijpddr.2012.04.001","volume":"2","author":"R Prichard","year":"2012","unstructured":"Prichard R, M\u00e9nez C, Lespine A. Moxidectin and the avermectins: consanguinity but not identity. Int J Parasitol Drugs Drug Resist. 2012;2:134\u201353.","journal-title":"Int J Parasitol Drugs Drug Resist."},{"key":"3632_CR36","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/BF01839009","volume":"16","author":"CP Daurio","year":"1992","unstructured":"Daurio CP, Cheung EN, Jeffcoat AR, Skelly BJ. Bioavailability of ivermectin administered orally to dogs. Vet Res Commun. 1992;16:125\u201330.","journal-title":"Vet Res Commun."},{"key":"3632_CR37","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1079\/9780851996172.0051","volume-title":"Macrocyclic lactones in Antiparasitic therapy","author":"M Jung","year":"2002","unstructured":"Jung M, Saito A, Buescher G, Maurer M, Graf JF. Chemistry, pharmacology and safety of the macrocyclic lactones: milbemycin oxime. In: Vercruysse J, Rew RS, editors. Macrocyclic lactones in Antiparasitic therapy. Wallingford: CABI Publishing; 2002. p. 51\u201374."},{"key":"3632_CR38","doi-asserted-by":"publisher","first-page":"e00381","DOI":"10.1128\/AAC.00381-17","volume":"61","author":"KE Mounsey","year":"2017","unstructured":"Mounsey KE, Walton SF, Innes A, Cash-Dean S, McCarthy J. In vitro efficacy of moxidectin versus ivermectin against Sarcoptes scabei. Antimicrob Agents Chemother. 2017;61:e00381\u2013417.","journal-title":"Antimicrob Agents Chemother."},{"key":"3632_CR39","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.vetpar.2004.11.010","volume":"128","author":"JB Lok","year":"2005","unstructured":"Lok JB, Knight DH, Nolan TJ, Grubbs ST, Cleale RM, Heaney K. Efficacy of an injectable, sustained-release formulation of moxidectin in preventing experimental HW infection in mongrel dogs challenged 12 months after administration. Vet Parasitol. 2005;128:129\u201335.","journal-title":"Vet Parasitol."},{"key":"3632_CR40","unstructured":"ProHeart 6\u00ae Freedom of Information Summary. 2001. \n                              https:\/\/animaldrugsatfda.fda.gov\/adafda\/app\/search\/public\/document\/downloadFoi\/700\n                              \n                           . Accessed 22 Apr 2019."},{"key":"3632_CR41","unstructured":"Cummings JC, Vickers L, Marbaugh J. Evaluation of veterinary dispensing records to measure \u201cclinic compliance\u201d with recommended heartworm prevention programs. In: Soll MD, editor. Proceedings of the Heartworm Symposium \u02bc95. Batavia, IL: American Heartworm Society; 1995. p. 115\u201320."},{"key":"3632_CR42","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/j.cvsm.2009.06.003","volume":"39","author":"DD Bowman","year":"2009","unstructured":"Bowman DD, Atkins CE. Heartworm biology, treatment, and control. Vet Clin North Am Small Anim Pract. 2009;39:1127\u201358.","journal-title":"Vet Clin North Am Small Anim Pract."},{"issue":"Suppl. 2","key":"3632_CR43","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1186\/s13071-017-2450-8","volume":"10","author":"TN Ku","year":"2017","unstructured":"Ku TN. Investigating management choices for canine HW disease in northern Mississippi. Parasit Vectors. 2017;10(Suppl. 2):474.","journal-title":"Parasit Vectors."},{"key":"3632_CR44","volume-title":"Compliance: taking quality care to the next level A report of the 2009 compliance follow-up study","author":"American Animal Hospital Association (AAHA)","year":"2009","unstructured":"American Animal Hospital Association (AAHA). Compliance: taking quality care to the next level A report of the 2009 compliance follow-up study. Lakewood: AAHA; 2009."},{"key":"3632_CR45","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.vetpar.2005.04.004","volume":"133","author":"VA Hampshire","year":"2005","unstructured":"Hampshire VA. Evaluation of efficacy of heartworm preventive products at the FDA. Vet Parasitol. 2005;133:191\u20135.","journal-title":"Vet Parasitol."},{"key":"3632_CR46","unstructured":"Pulaski C, Shibukawa-Kent R, Bright-Ponte S, Duggirala H, Baker J, Malone J, et al. Heartworm preventive drug \u2018lack of effectiveness\u2019 claims submitted to the FDA (2004\u20132015): an analysis of reports and further application. American Association of Veterinary Parasitologists, 62nd Annual Meeting, July 22\u201325th, Indianapolis, IN, USA; 2017."},{"key":"3632_CR47","unstructured":"NexGard, 2014. Nexgard Spectra (EMEA\/V\/C\/003842\/0000) EMA\/695949\/2014. Committee for Medicinal Products for Veterinary Use (CVMP) Assessment Report (EPAR), 21\u201322."},{"issue":"Suppl. 2","key":"3632_CR48","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1186\/s13071-017-2430-z","volume":"10","author":"TL McTier","year":"2017","unstructured":"McTier TL, Pullins A, Inskeep GA, Gagnon G, Fan H, Schoell A, et al. Microfilarial reduction following ProHeart\u00ae 6 and ProHeart\u00ae SR-12 treatment in dogs experimentally inoculated with a resistant isolate of Dirofilaria immitis. Parasit Vectors. 2017;10(Suppl. 2):485.","journal-title":"Parasit Vectors."},{"key":"3632_CR49","unstructured":"McTier TL, McCall JW, Dzimianski MT, Raynaud JP, Holmes RA, Keister DM. Epidemiology of HW infection studied by using naturally exposed \u201ctracer\u201d beagles in three southeastern states. In: Soll MD, editor. Proceedings of the HW Symposium \u02bc92. Batavia, IL: American Heartworm Society; 1992. p. 47\u201357."},{"key":"3632_CR50","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1186\/1756-3305-7-264","volume":"7","author":"D Wang","year":"2014","unstructured":"Wang D, Bowman DD, Brown HE, Harrington LC, Kaufman PE, McKay T, et al. Factors influencing US canine heartworm (Dirofilaria immitis) prevalence. Parasit Vectors. 2014;7:264.","journal-title":"Parasit Vectors."},{"key":"3632_CR51","unstructured":"Safeheart\u2122 (milbemycin oxime oral tablets) FOI. 1998. \n                              https:\/\/animaldrugsatfda.fda.gov\/adafda\/app\/search\/public\/document\/downloadFoi\/528\n                              \n                           . Accessed 16 Nov 2018."},{"key":"3632_CR52","unstructured":"Heartgard\u00ae 30 (ivermectin oral tablets) FOI. 1987. \n                              https:\/\/animaldrugsatfda.fda.gov\/adafda\/app\/search\/public\/document\/downloadFoi\/420\n                              \n                           . Accessed 16 Nov 2018."}],"container-title":["Parasites & Vectors"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13071-019-3632-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13071-019-3632-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13071-019-3632-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T23:10:20Z","timestamp":1595632220000},"score":1,"resource":{"primary":{"URL":"https:\/\/parasitesandvectors.biomedcentral.com\/articles\/10.1186\/s13071-019-3632-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,26]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["3632"],"URL":"https:\/\/doi.org\/10.1186\/s13071-019-3632-3","relation":{},"ISSN":["1756-3305"],"issn-type":[{"value":"1756-3305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,26]]},"assertion":[{"value":"1 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Laboratory study protocols were reviewed and approved by the Institutional Animal Care and Use Committee at each facility. The field efficacy study protocol was reviewed by the Zoetis Ethical Review Board (Kalamazoo, MI), and each owner gave written informed consent for enrollment of their dog in the study. All three studies were conducted according to state and national regulations regarding animal welfare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"TM, KK, MW and SM are current employees of Zoetis. DR, DR, MM are former employees of Zoetis. CT, EA, TW and DB declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"369"}}